Skip to content

Pasadena Star News

63°F
Monday, January 26th 2026

e-Edition

Trending:

Recent Quotes
My Watchlist
Indicators
Local Stocks
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vertex Pharmaceuticals (NQ:VRTX)

477.80 +9.38 (+2.00%)
Streaming Delayed Price Updated: 2:46 PM EST, Jan 26, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Vertex Pharmaceuticals

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Breaking Barriers: How 2026’s Top Clinical Leaders Are Disrupting Chronic Disease Markets
Issued on behalf of Avant Technologies Inc. 
From Equity Insider
Via GlobeNewswire
News headline image
Vertex to Announce Fourth Quarter and Full Year 2025 Financial Results on February 12th
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
Vertex to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 12
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
From Insulin Injections to Functional Cures: Regenerative Medicine Reshapes Diabetes
Issued on behalf of Avant Technologies Inc. 
From USA News Group
Via GlobeNewswire
News headline image
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
Vertex to Participate in the Citi’s 2025 Global Healthcare Conference on December 3
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
Vertex Presents Updated Phase 1/2 Data From RUBY-3 Study That Continue to Demonstrate Best-in-Class Potential for Povetacicept in Adults with IgA Nephropathy and Primary Membranous Nephropathy at American Society of Nephrology Kidney Week
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
Vertex Reports Third Quarter 2025 Financial Results
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
Vertex to Participate in the UBS Global Healthcare Conference on November 11
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
Vertex Presents New Data Across Portfolio of Cystic Fibrosis Medicines Including ALYFTREK® at the North American Cystic Fibrosis Conference
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
Vertex to Announce Third Quarter 2025 Financial Results on November 3rd
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
Vertex Announces Key Advancements Across Kidney Portfolio
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
Vertex Partners with Basketball World Champion Jayson Tatum to Raise Awareness of JOURNAVX®, a Non-Opioid Medicine Approved for the Treatment of Moderate-to-Severe-Acute Pain
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
Vertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Transfusion-Dependent Beta Thalassemia and Sickle Cell Disease in Italy
From Vertex Pharmaceuticals
Via Business Wire
News headline image
Vertex Scientists Awarded the 2025 Lasker~DeBakey Clinical Medical Research Award for Pioneering Discoveries in Cystic Fibrosis
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
Vertex to Participate in Upcoming September Investor Conferences
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
Vertex Reports Second Quarter 2025 Financial Results
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
Vertex Announces Results from Phase 2 Study of VX-993 for the Treatment of Acute Pain
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
Vertex Named a Premier, Inc. Breakthroughs Innovation Celebration Winner for JOURNAVX™, a First-in-Class Non-Opioid Treatment for Adults With Moderate-to-Severe Acute Pain
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Breaking Through: Systemic Genetic Medicines for Hard-to-Treat Cancers
Via Investor Brand Network
News headline image
Breaking Through: Systemic Genetic Medicines for Hard-to-Treat Cancers
EQNX::TICKER_START (NYSE:CLDI),(NASDAQ:VRTX),(NASDAQ:IBRX),(NASDAQ:CRSP),(NASDAQ:CTMX) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Death
News headline image
Vertex to Announce Second Quarter 2025 Financial Results on August 4th
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
Precision Genetic Medicine Platform Could Disrupt Standard of Care in Metastatic Cancer, Other Indications of Unmet Needs
EQNX::TICKER_START (NYSE:CLDI),(NASDAQ:REGN),(NASDAQ:VRTX),(OTCQX:RHHBY),(NYSE:MRK) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Death
News headline image
Vertex and Ono Pharmaceutical Announce Strategic Agreement to Develop and Commercialize Povetacicept in Japan and South Korea
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
Vertex Presents Positive Data for Zimislecel in Type 1 Diabetes at the American Diabetes Association 85th Scientific Sessions
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
Vertex Presents New Data on Benefits of ALYFTREK® and Importance of Achieving Lower Sweat Chloride Levels at the European Cystic Fibrosis Conference
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
Vertex to Participate in Upcoming Investor Conferences
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
Vertex Reports First Quarter 2025 Financial Results
From Vertex Pharmaceuticals Incorporated
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.